Pulse Biosciences, Inc.
$20.99
-0.42 (-1.96%)
PLSE Price Chart
| Basic | |
|---|---|
| Market Cap | $1.32B |
| Price | $20.99 |
| 52 Week Range | 6.595-25 |
| Beta | 1.75 |
| Margins | |
| Gross Profit Margin | 0.00% |
| Operating Profit Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Valuation (TTM) | |
| P/E Ratio | -17.36 |
| Price to Sales Ratio | 0.00 |
| Price to Book Ratio | 8.10 |
| PEG Ratio | 1.41 |
Industry
Medical - Instruments & Supplies
Sector
Healthcare
Full-Time Employees
56
IPO Date
2016-05-18T00:00:00.000Z
Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Phone
510 906 4600
Address
3957 Point Eden Way, Hayward, CA, 94545, US
CIK
0001625101